Αρχική World News Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma Subtypes

Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma Subtypes

Findings from a registry study presented at the ESMO Asia Virtual Congress 2020, held from 20 to 22 November 2020 provided the first step in formulating cohesive treatment strategies for T-cell non-Hodgkin lymphomas (NHLs) by identifying the prevalence of subtypes, treatments, and patient outcomes across several Asian countries.

Sang Eun Yoon of the Hematology, Samsung Medical Center in Seoul, Republic of Korea, discussed the difficulties in treating peripheral T-cell lymphomas (PTCLs), which are uncommon and regionally heterogeneous malignancies. Furthermore, there is no consensus regarding treatment of T-cell NHLs with most studies being conducted individually in each country, with no assessment of the incidence across Asia.

In order to resolve these issues, Professor Yoon and collegues conducted this Asian-specific study to determine the incidence of T-cell NHLs and identified majority-approved treatments across the region. They initiated the multinational, multicentre prospective intercontinental registry study by reviewing the registries of 32 institutes in China, Taiwan, Singapore, Indonesia, and the Republic of Korea from April 2016 to February 2019 to identify patients with PTCLs.

The investigators determined the most often used therapies and the corresponding patient outcomes

The registry review identified 486 cases; across all subtypes of T-cell NHLs, the median patient age was 57 (range, 19-89) years, about 60% of patients were men and had B-symptoms. The percentage of patients with stage 3 or 4 diseases was about 60%.  

Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) was the most prevalent subtype with an incidence of 28.6%, followed by angioimmunoblastic T-cell lymphoma (AITL; 24.7%), and peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS; 20.8%).

Intercontinental-Asian-Study-Compiles-the-Relative-Incidence-of-non-Hodgkin-T-cell-Lymphoma-Subtypes-Fig1

Incidence of non-Hodgkin T-cell lymphoma subtypes in prospective registry study in Asia.

© Sang Eun Yoon.

We compared the PFS and OS according to the five most common subtypes (ENKTL, AITL, PTCL-NOS, ALK-positive ALCL, ALK-negative ALCL), ALK-positive anaplastic large cell lymphoma (ALCL) had more favorable PFS compared to the others.

Intercontinental-Asian-Study-Compiles-the-Relative-Incidence-of-non-Hodgkin-T-cell-Lymphoma-Subtypes-Fig2

Progression-free survival curves for most prevalent subtypes in the registry.

© Sang Eun Yoon.

Intercontinental-Asian-Study-Compiles-the-Relative-Incidence-of-non-Hodgkin-T-cell-Lymphoma-Subtypes-Fig3

Overall survival curves for most prevalent subtypes in the registry.

© Sang Eun Yoon.

Patients treated with chemoradiotherapy had demonstrated superior objective response rates and PFS, as compared to chemotherapy only (p = 0.03). Advanced ENKTL patients who underwent upfront autologous stem cell transplantation (auto-SCT) after frontline cytotoxic chemotherapy achieved superior outcomes compared to those who did not (p = 0.04).

The predominant treatments for PTCL-NOS, AITL, and ALCL were CHOP-like (cyclophosphamide, doxorubicin, vincristine, and prednisolone) and CHOEP-like (CHOP plus etoposide) regimens across Asia. However, no significant difference was found in the survival benefit between these regimens (CHOP-like versus CHOEP like, versus others; p = 0.68). Besides, CHOP-like and CHOEP-like regimes showed no critical difference in PFS across all age groups as well as in age-dependent groups.

Regarding treatments used in the salvage setting, cytotoxic chemotherapy showed disappointing efficacy, and superiority was not decisive yet for any salvage strategies regardless of all subtypes.

Conclusions

The investigators were able to determine the relative incidence of T-cell lymphoma and the corresponding survival outcomes across Asia. They concluded that the intercontinental study was meaningful as the first PTCLs registry study in Asia.

They noted that the study may be limited by bias in the registration of patients due to the large number of patients registered in some countries.

No external funding was disclosed.

Reference

257O – Yoon SE, Song Y, Kim SJ et al. Intercontinental cooperative non-Hodgkin T-cell lymphoma prospective registry study in Asia: ICT study. ESMO Asia Virtual Congress 2020 (20-22 November).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...